At least nine significant funding rounds in Q1 2026 brought total BCI investment past $960 million, with capital spreading across invasive, endovascular, ultrasound, and neurostimulation modalities.
Four states now classify brain data as sensitive personal information, with at least seven more bills advancing in 2026 — but definitions vary widely and no federal standard is in sight.
The startup, led by iota Biosciences founder Michel Maharbiz, is developing a minimally invasive brain-computer interface that pairs neural decoding with a motorized grip-assist glove to restore movement after stroke.
The Austin-based company is now enrolling participants at the University of Michigan and Massachusetts General Hospital for the Connect-One study, the first clinical trial of a fully implantable BCI designed to restore speech.
A four-day invitation-only summit modelled on the landmark 1975 DNA conference brings together neuroethicists, investors, and policymakers to create practical governance tools for the BCI industry.
Sam Altman's brain-computer interface startup raised the second-largest BCI round in history. The scientific community is asking whether the physics adds up.
The second annual forum brought together device makers, investors, and six early-stage startups for two days of panels on BCI, neuromodulation, and digital health.
Four philosophers at Glasgow and Oxford will lead a new interdisciplinary lab examining the ethical and epistemological implications of brain-computer interfaces.
The FOCUS-AU trial will test Synchron's advanced brain-computer interface in ten MND patients across three Australian hospitals, with surgery beginning in April.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.